The unaudited supplemental pro forma financial information presented below has been prepared as if the Semler Scientific Merger had occurred in the earliest presented period. The pro forma financial information is developed using estimates and assumptions based on information available at the time. The Company believes such estimates and assumptions to be reasonable; however, the unaudited pro forma financial information is not necessarily indicative of what the combined company's results would have been had the acquisition been completed as of the beginning of the periods as indicated, nor does it purport to represent the Company's future results. There are no pro forma adjustments for the three months ended September 30, 2026. As the financial information for the period from July 1, 2025 to September 11, 2025 and the period from January 1, 2025 to September 11, 2025 represent the financial information of the Predecessor, no such pro forma financial information has been included. Amounts below are presented in thousands, other than per-share amounts. | | | | | | | | | | | | | Nine Months Ended September 30, 2026 | | Period From September 12, 2025 to September 30, 2025 | | Total revenues | $ | 8,786 | | | $ | 1,753 | | | Net loss before income taxes | $ | (15,610) | | | $ | (206,116) | |
|